Cargando…

Budget Impact Analysis of Pharmacist-Led Medication Management in Cardiovascular and Type 2 Diabetic Patients

The paper aims to identify and measure the costs and savings associated with the delivery of Comprehensive Medication Management (CMM) services in Croatia in patients diagnosed with hypertension accompanied by at least one additional established cardiovascular disease (CVD) and/or type 2 diabetes me...

Descripción completa

Detalles Bibliográficos
Autores principales: Mucalo, Iva, Brajković, Andrea, Strgačić, Marija, Ramalho-de-Oliveira, Djenane, Ribarić, Elizabeta, Bobinac, Ana
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027851/
https://www.ncbi.nlm.nih.gov/pubmed/35455900
http://dx.doi.org/10.3390/healthcare10040722
_version_ 1784691470281736192
author Mucalo, Iva
Brajković, Andrea
Strgačić, Marija
Ramalho-de-Oliveira, Djenane
Ribarić, Elizabeta
Bobinac, Ana
author_facet Mucalo, Iva
Brajković, Andrea
Strgačić, Marija
Ramalho-de-Oliveira, Djenane
Ribarić, Elizabeta
Bobinac, Ana
author_sort Mucalo, Iva
collection PubMed
description The paper aims to identify and measure the costs and savings associated with the delivery of Comprehensive Medication Management (CMM) services in Croatia in patients diagnosed with hypertension accompanied by at least one additional established cardiovascular disease (CVD) and/or type 2 diabetes mellitus (DMT2) who use five or more medicines daily. The budget impact analysis (BIA) employed in this study compares the total costs of CMM to the cost reductions expected from CMM. The cost reductions (or savings) are based on the reduced incidence of unwanted clinical events and healthcare service utilisation rates due to CMM. The BIA model is populated by data on medication therapy costs, labour, and training from the pilot CMM intervention introduced in Zagreb’s main Health Centre, while relevant international published sources were used to estimate the utilisation, incidence, and unwanted clinical events rates. Total direct costs, including pharmacists’ labour and training (EUR 2,667,098) and the increase in the cost of prescribed medication (EUR 5,182,864) amounted to EUR 7,849,962 for 3 years, rendering the cost per treated patient per year EUR 57. CMM is expected to reduce the utilisation rates of healthcare services and the incidence of unwanted clinical events, leading to a total 3-year reduction in healthcare costs of EUR 7,787,765. Given the total CMM costs of EUR 7,849,962, CMM’s 3-year budget impact equals EUR 92,869, rendering per treated patient an incremental cost of CMM EUR 0.67. Hence, CMM appears to be an affordable intervention for addressing medication mismanagement and irrational drug use.
format Online
Article
Text
id pubmed-9027851
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-90278512022-04-23 Budget Impact Analysis of Pharmacist-Led Medication Management in Cardiovascular and Type 2 Diabetic Patients Mucalo, Iva Brajković, Andrea Strgačić, Marija Ramalho-de-Oliveira, Djenane Ribarić, Elizabeta Bobinac, Ana Healthcare (Basel) Article The paper aims to identify and measure the costs and savings associated with the delivery of Comprehensive Medication Management (CMM) services in Croatia in patients diagnosed with hypertension accompanied by at least one additional established cardiovascular disease (CVD) and/or type 2 diabetes mellitus (DMT2) who use five or more medicines daily. The budget impact analysis (BIA) employed in this study compares the total costs of CMM to the cost reductions expected from CMM. The cost reductions (or savings) are based on the reduced incidence of unwanted clinical events and healthcare service utilisation rates due to CMM. The BIA model is populated by data on medication therapy costs, labour, and training from the pilot CMM intervention introduced in Zagreb’s main Health Centre, while relevant international published sources were used to estimate the utilisation, incidence, and unwanted clinical events rates. Total direct costs, including pharmacists’ labour and training (EUR 2,667,098) and the increase in the cost of prescribed medication (EUR 5,182,864) amounted to EUR 7,849,962 for 3 years, rendering the cost per treated patient per year EUR 57. CMM is expected to reduce the utilisation rates of healthcare services and the incidence of unwanted clinical events, leading to a total 3-year reduction in healthcare costs of EUR 7,787,765. Given the total CMM costs of EUR 7,849,962, CMM’s 3-year budget impact equals EUR 92,869, rendering per treated patient an incremental cost of CMM EUR 0.67. Hence, CMM appears to be an affordable intervention for addressing medication mismanagement and irrational drug use. MDPI 2022-04-13 /pmc/articles/PMC9027851/ /pubmed/35455900 http://dx.doi.org/10.3390/healthcare10040722 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Mucalo, Iva
Brajković, Andrea
Strgačić, Marija
Ramalho-de-Oliveira, Djenane
Ribarić, Elizabeta
Bobinac, Ana
Budget Impact Analysis of Pharmacist-Led Medication Management in Cardiovascular and Type 2 Diabetic Patients
title Budget Impact Analysis of Pharmacist-Led Medication Management in Cardiovascular and Type 2 Diabetic Patients
title_full Budget Impact Analysis of Pharmacist-Led Medication Management in Cardiovascular and Type 2 Diabetic Patients
title_fullStr Budget Impact Analysis of Pharmacist-Led Medication Management in Cardiovascular and Type 2 Diabetic Patients
title_full_unstemmed Budget Impact Analysis of Pharmacist-Led Medication Management in Cardiovascular and Type 2 Diabetic Patients
title_short Budget Impact Analysis of Pharmacist-Led Medication Management in Cardiovascular and Type 2 Diabetic Patients
title_sort budget impact analysis of pharmacist-led medication management in cardiovascular and type 2 diabetic patients
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9027851/
https://www.ncbi.nlm.nih.gov/pubmed/35455900
http://dx.doi.org/10.3390/healthcare10040722
work_keys_str_mv AT mucaloiva budgetimpactanalysisofpharmacistledmedicationmanagementincardiovascularandtype2diabeticpatients
AT brajkovicandrea budgetimpactanalysisofpharmacistledmedicationmanagementincardiovascularandtype2diabeticpatients
AT strgacicmarija budgetimpactanalysisofpharmacistledmedicationmanagementincardiovascularandtype2diabeticpatients
AT ramalhodeoliveiradjenane budgetimpactanalysisofpharmacistledmedicationmanagementincardiovascularandtype2diabeticpatients
AT ribaricelizabeta budgetimpactanalysisofpharmacistledmedicationmanagementincardiovascularandtype2diabeticpatients
AT bobinacana budgetimpactanalysisofpharmacistledmedicationmanagementincardiovascularandtype2diabeticpatients